Table 1.
Patient Characteristics
| Characteristic | Warfarin, N=474 | DOAC, N=302 | P value |
|---|---|---|---|
| Age, y, mean±SD | 58.4±16.8 | 57.7±16.9 | 0.58 |
| Women, n (%) | 263 (55.5) | 212 (70.2) | <0.001 |
| Race | |||
| White, n (%) | 337 (71.1) | 221 (73.2) | 0.18 |
| Black, n (%) | 82 (17.3) | 58 (19.2) | |
| Other, n (%) | 55 (11.6) | 23 (7.6) | |
| Insurance | |||
| Medicare, n (%) | 178 (37.6) | 97 (32.1) | 0.12 |
| Medicaid, n (%) | 17 (3.6) | 29 (9.6) | <0.001 |
| Private insurance, n (%) | 271 (57.2) | 185 (61.3) | 0.26 |
| Other, n (%) | 8 (1.7) | 8 (2.7) | 0.36 |
| Indication | |||
| DVT only, n (%) | 363 (76.6) | 172 (57.0) | <0.001 |
| PE with or without DVT, n (%) | 111 (23.4) | 130 (43.1) | <0.001 |
| Change to reduced dose at any time, n (%) | … | 16 (5.3) | … |
| Change to reduced dose after 3 mo, n (%) | … | 12 (4.0) | … |
| Recurrent VTE, n (%) | 88 (18.6) | 17 (5.6) | <0.001 |
| History of cancer, n (%) | 95 (20.0) | 61 (20.2) | 0.96 |
| History of chronic heart failure | 31 (6.5) | 12 (4.0) | 0.13 |
| History of stroke/TIA | 33 (7.0) | 17 (5.6) | 0.46 |
| History of gastrointestinal bleed | 26 (5.5) | 16 (5.3) | 0.91 |
| History of myocardial infarction | 17 (3.6) | 14 (4.6) | 0.47 |
| Chronic liver disease | 14 (3.0) | 11 (3.6) | 0.60 |
| History of renal disease, n (%) | 46 (9.7) | 23 (7.6) | 0.32 |
| NSAID use, n (%) | 32 (6.8) | 12 (4) | 0.10 |
| Concurrent antiplatelet, n (%) | 141 (29.8) | 66 (21.9) | 0.015 |
| Recent bleeding, within 30 d of VTE, n (%) | 25 (5.3) | 36 (11.9) | <0.001 |
| Provoking conditions, n (%) | |||
| Surgery | 394 (83.1) | 208 (68.9) | <0.001 |
| Casting/immobilization | 99 (20.9) | 83 (27.5) | 0.034 |
| Childbirth | 8 (1.7) | 4 (1.3) | 0.69 |
| Oral contraceptives | 44 (9.3) | 59 (19.5) | <0.001 |
Data were obtained using a t test for means and Fischer exact test and χ2 test for percentages. Other race includes patient races other than Black or White as well as patients with multiple races selected or no race data available. DOAC indicates direct oral anticoagulant; DVT, deep vein thrombosis; NSAID, nonsteroidal anti‐inflammatory drug; PE, pulmonary embolism; TIA, transient ischemic attack; and VTE, venous thromboembolism.